Skip to main content
. 2022 Jan 14;12:794780. doi: 10.3389/fimmu.2021.794780

Figure 1.

Figure 1

The molecular interactions of (A, B) N3 inhibitor, (C, D) psilacetin, (E, F) psilocin, and (G, H) psilocybine with the active pocket of SARS-CoV-2 Mprotease. The structure indicated different residual interactions.